glp-1 parkinson's disease Glucagon-like peptide-1 medicines in neurological and psychiatric disorders: Cell Reports Medicine Targeting Metabolic Dysfunction in Parkinson's

Bioengineered exosomal-membrane-camouflaged abiotic nanocarriers: neurodegenerative diseases, tissue engineering and regenerative medicine

Should I take both Flatter Me and Flatter Me PLUS

Endocrinology and metabolism 295, E13231332, doi: 10.1152/ajpendo.90617.2008 (2008)

Structure of the full-length glucagon class B G-protein-coupled receptor

A multicenter, single-blind randomized, controlled study of a volumizing hyaluronic acid filler for midface volume deficit: patient-reported outcomes at 2 years

Furthermore, understanding the functionality of the GLP-1R may help in development of more specific GLP-1 analogs (Patterson et al., 2013)